Download our Application Note “Anti-LRP5/6 VHH inhibits WNT pathway and prevents tumour growth”
Anti-LRP5/6P3 VHH treatment not only blocks cellular responses to Wnt3 but also removes the main source of Wnt production. Learn more with this application note.
Abstract:
VHH are the variable domain of heavy chain only antibodies. They are small in size (~15 kD) and biophysically robust. With tunable half-lives, these antibodies are ideal for targeting inaccessible epitopes, achieving enhanced tissue penetration, multi-target binding and formatting for payload delivery…
Who should read this:?
- Researchers in antibody discovery, engineering and development
- Thought leaders in antibody development
Note: It is our responsibility to protect your privacy and we guarantee that your data will be completely confidential.
